AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.07B
1-Year Est. Return
86.9%
1 Year Est. Return
+86.9%
AUM
$1.07B
AUM Growth
+$399M
(+59%)
Holding
110
Top Buys
| 1 | +$56.3M | |
| 2 | +$22.1M | |
| 3 | +$20.3M | |
| 4 |
Cytokinetics
CYTK
|
+$19.2M |
| 5 |
Apogee Therapeutics
APGE
|
+$19.1M |
Top Sells
| 1 | +$32M | |
| 2 | +$14.6M | |
| 3 | +$11.2M | |
| 4 |
Vera Therapeutics
VERA
|
+$7.02M |
| 5 |
INZY
Inozyme Pharma
INZY
|
+$7M |
Sector Composition
| 1 | Healthcare | 91.07% |
| 2 | Financials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
1
DELISTED
Verona Pharma
VRNA
| $66.7M | 5.81% |
625,000
+15,000
|
|
||
2
Insmed
INSM
$45.1B
| $64.8M | 5.65% |
450,000
-25,000
|
|
||
3
SPDR S&P 500 ETF Trust
SPY
$697B
| $56.3M | 4.9% |
+84,490
|
|
||
4
Xenon Pharmaceuticals
XENE
$3.36B
| $56.2M | 4.9% |
1,400,000
+300,000
|
|
||
5
Madrigal Pharmaceuticals
MDGL
$13.2B
| $52.7M | 4.59% |
115,000
+35,000
|
|
||
|
6
Apogee Therapeutics
APGE
$4.71B
| $46.6M | 4.06% |
1,173,426
+481,527
|
|
||
7
Arcellx
ACLX
$4.06B
| $41M | 3.58% |
500,000
+5,000
|
|
||
8
Alkermes
ALKS
$4.77B
| $37.5M | 3.27% |
1,250,000
+250,000
|
|
||
9
Nuvalent
NUVL
$8.26B
| $33.2M | 2.9% |
384,417
-30,583
|
|
||
|
ABVX
10
Abivax
ABVX
$9.34B
| $30.6M | 2.66% |
360,000
+260,000
|
|
||
11
Mineralys Therapeutics
MLYS
$3.22B
| $28.4M | 2.48% |
750,000
-150,000
|
|
||
12
Teva Pharmaceuticals
TEVA
$30.7B
| $28.3M | 2.46% |
1,400,000
|
|
||
13
Merus
MRUS
$7.28B
| $26.9M | 2.34% |
285,769
+215,769
|
|
||
|
CNTA
14
Centessa Pharmaceuticals
CNTA
$4.21B
| $26.8M | 2.34% |
1,107,162
+207,000
|
|
||
15
Lexeo Therapeutics
LXEO
$651M
| $25.7M | 2.24% |
3,870,527
+281,172
|
|
||
16
Trevi Therapeutics
TRVI
$1.71B
| $25.6M | 2.23% |
2,800,000
+265,942
|
|
||
17
Spyre Therapeutics
SYRE
$2.22B
| $23.8M | 2.07% |
1,419,299
+812,621
|
|
||
18
Rezolute
RZLT
$850M
| $19.7M | 1.72% |
2,100,000
-100,000
|
|
||
|
19
Cytokinetics
CYTK
$8.08B
| $19.2M | 1.68% |
+350,000
|
|
||
|
ORKA
20
Oruka Therapeutics
ORKA
$1.34B
| $18.4M | 1.61% |
959,180
+355,701
|
|
||
21
uniQure
QURE
$1.66B
| $17.5M | 1.53% |
300,000
+165,000
|
|
||
22
Wave Life Sciences
WVE
$1.24B
| $15.4M | 1.34% |
2,100,000
+99,692
|
|
||
23
Protagonist Therapeutics
PTGX
$5.35B
| $14.7M | 1.28% |
220,600
-219,400
|
|
||
24
Soleno Therapeutics
SLNO
$2.63B
| $13.5M | 1.18% |
+200,000
|
|
||
25
Avalo Therapeutics
AVTX
$304M
| $12.8M | 1.11% |
1,006,217
+398,345
|
|